Compare TG Therapeutics Inc (TGTX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Xpeng Inc - ADR — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: TG Therapeutics Inc and Xpeng Inc - ADR are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Xpeng Inc - ADR for 80 Days on average.
| TGTX | XPEV | |
|---|---|---|
Market Cap | $8.16B | $9.16B |
Volume | 1,735,121 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $28.07 |
52-Week Low | $26.94 | $9.25 |
Typical Hold Time | 16 Days | 80 Days |
Enterprise Value | $8.37B | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
XPeng (XPEV) trades at $9.55, down 0.31% with a bearish technical signal. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a net margin of -4.14%. Recent vehicle deliveries of 41,256 in September 2026 and the upcoming G9L SUV launch at the Paris Motor Show highlight expansion efforts. Analyst consensus is bullish with a $17.55 price target, though earnings misses in Q1 and Q2 2026 raise execution concerns.
The stock presents a high-risk, high-reward opportunity. Significant revenue growth and analyst optimism are offset by persistent losses and competitive pressures. Key catalysts include successful global expansion and profitability improvements, while risks involve execution missteps and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
